 Connection
Rajesh Agarwal to Clinical Trials as Topic
This is a "connection" page, showing publications Rajesh Agarwal has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.277 |
|
|
|
-
Deep G, Agarwal R. New combination therapies with cell-cycle agents. Curr Opin Investig Drugs. 2008 Jun; 9(6):591-604.
Score: 0.053
-
Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008 Oct 08; 269(2):352-62.
Score: 0.052
-
Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther. 2007 Jun; 6(2):130-45.
Score: 0.049
-
Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol. 2007 Nov 01; 224(3):350-9.
Score: 0.047
-
Singh RP, Agarwal R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog. 2006 Jun; 45(6):436-42.
Score: 0.046
-
Puri R, Mehta V, Duell PB, Nair D, Mohan JC, Yusuf J, Dalal JJ, Mishra S, Kasliwal RR, Agarwal R, Mukhopadhyay S, Wardhan H, Khanna NN, Pradhan A, Mehrotra R, Kumar A, Puri S, Muruganathan A, Sattur GB, Yadav M, Singh HP, Agarwal RK, Nanda R. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. J Clin Lipidol. 2020 Mar - Apr; 14(2):e1-e13.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|